Cargando…

Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hypercholesterolemia and atherosclerosis. Recently, PCSK9 has been implicated in the pathogenesis of inflammatory diseases. Whether PCSK9 is involved in idiopathic pulmonary arterial hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Dong-Xiang, Zhang, Yuan, Jin, Qi, Zhang, Xiao-Chun, Zhang, Feng, Chen, Dan-Dan, Guan, Li-Hua, Zhou, Da-Xin, Ge, Jun-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516391/
https://www.ncbi.nlm.nih.gov/pubmed/34659741
http://dx.doi.org/10.1177/20458940211051292
_version_ 1784583797157658624
author Zhong, Dong-Xiang
Zhang, Yuan
Jin, Qi
Zhang, Xiao-Chun
Zhang, Feng
Chen, Dan-Dan
Guan, Li-Hua
Zhou, Da-Xin
Ge, Jun-Bo
author_facet Zhong, Dong-Xiang
Zhang, Yuan
Jin, Qi
Zhang, Xiao-Chun
Zhang, Feng
Chen, Dan-Dan
Guan, Li-Hua
Zhou, Da-Xin
Ge, Jun-Bo
author_sort Zhong, Dong-Xiang
collection PubMed
description Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hypercholesterolemia and atherosclerosis. Recently, PCSK9 has been implicated in the pathogenesis of inflammatory diseases. Whether PCSK9 is involved in idiopathic pulmonary arterial hypertension (IPAH) remains unclear. This study aimed to investigate the relationship between PCSK9 and IPAH. Serum PCSK9, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), and monocyte chemotactic protein-1 (MCP-1) were measured by enzyme linked immunosorbent assay. Transthoracic echocardiography was performed among 40 IPAH patients and 20 control subjects. Hemodynamic data were collected via right heart catheterization in patients with IPAH. Serum PCSK9, TNF-α, IL-6, IL-1β, and MCP-1 levels were significantly higher in IPAH patients than in control subjects (p < 0.001). Among enrolled IPAH patients, PCSK9 levels were higher in WHO-FC III/IV patients compared with those in WHO-FC I/II (p < 0.05), and were positively correlated with TNF-α, IL-6, MCP-1, N-Terminal pro-brain natriuretic peptide, pulmonary arterial systolic pressure (r = 0.653, p < 0.001), pulmonary arterial diastolic pressure (r = 0.466, p = 0.002), mean pulmonary arterial pressure (mPAP, r = 0.730, <0.001), pulmonary vascular resistance (r = 0.488, p = 0.001), and right ventricle diameter (r = 0.563, p < 0.001). In multiple regression analysis, mPAP was strongly associated with serum PCSK9 (β = 0.694, p < 0.001), independent of other variables. Receiver operating characteristic curve analysis showed the optimal cutoff value of serum PCSK9 concentration for predicting IPAH was 90.67 ng/ml, with a sensitivity of 90.0% and a specificity of 85.0%. In conclusion, IPAH patients had elevated serum PCSK9 levels which correlated the presence and severity of pulmonary hypertension. PCSK9 may be a novel potential therapeutic target.
format Online
Article
Text
id pubmed-8516391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85163912021-10-15 Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines Zhong, Dong-Xiang Zhang, Yuan Jin, Qi Zhang, Xiao-Chun Zhang, Feng Chen, Dan-Dan Guan, Li-Hua Zhou, Da-Xin Ge, Jun-Bo Pulm Circ Original Research Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hypercholesterolemia and atherosclerosis. Recently, PCSK9 has been implicated in the pathogenesis of inflammatory diseases. Whether PCSK9 is involved in idiopathic pulmonary arterial hypertension (IPAH) remains unclear. This study aimed to investigate the relationship between PCSK9 and IPAH. Serum PCSK9, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), and monocyte chemotactic protein-1 (MCP-1) were measured by enzyme linked immunosorbent assay. Transthoracic echocardiography was performed among 40 IPAH patients and 20 control subjects. Hemodynamic data were collected via right heart catheterization in patients with IPAH. Serum PCSK9, TNF-α, IL-6, IL-1β, and MCP-1 levels were significantly higher in IPAH patients than in control subjects (p < 0.001). Among enrolled IPAH patients, PCSK9 levels were higher in WHO-FC III/IV patients compared with those in WHO-FC I/II (p < 0.05), and were positively correlated with TNF-α, IL-6, MCP-1, N-Terminal pro-brain natriuretic peptide, pulmonary arterial systolic pressure (r = 0.653, p < 0.001), pulmonary arterial diastolic pressure (r = 0.466, p = 0.002), mean pulmonary arterial pressure (mPAP, r = 0.730, <0.001), pulmonary vascular resistance (r = 0.488, p = 0.001), and right ventricle diameter (r = 0.563, p < 0.001). In multiple regression analysis, mPAP was strongly associated with serum PCSK9 (β = 0.694, p < 0.001), independent of other variables. Receiver operating characteristic curve analysis showed the optimal cutoff value of serum PCSK9 concentration for predicting IPAH was 90.67 ng/ml, with a sensitivity of 90.0% and a specificity of 85.0%. In conclusion, IPAH patients had elevated serum PCSK9 levels which correlated the presence and severity of pulmonary hypertension. PCSK9 may be a novel potential therapeutic target. SAGE Publications 2021-10-12 /pmc/articles/PMC8516391/ /pubmed/34659741 http://dx.doi.org/10.1177/20458940211051292 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Zhong, Dong-Xiang
Zhang, Yuan
Jin, Qi
Zhang, Xiao-Chun
Zhang, Feng
Chen, Dan-Dan
Guan, Li-Hua
Zhou, Da-Xin
Ge, Jun-Bo
Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title_full Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title_fullStr Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title_full_unstemmed Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title_short Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
title_sort increased serum pcsk9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516391/
https://www.ncbi.nlm.nih.gov/pubmed/34659741
http://dx.doi.org/10.1177/20458940211051292
work_keys_str_mv AT zhongdongxiang increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT zhangyuan increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT jinqi increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT zhangxiaochun increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT zhangfeng increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT chendandan increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT guanlihua increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT zhoudaxin increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines
AT gejunbo increasedserumpcsk9inpatientswithidiopathicpulmonaryarterialhypertensioninsightsfrominflammatorycytokines